Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trialPaul R. Kalra, Claes Christian Strom, Mark C. Petrie et al.|The Lancet|2022Cited by 367